| ESR1 ligand-binding domain mutations in hormone-resistant breast cancer W Toy, Y Shen, H Won, B Green, RA Sakr, M Will, Z Li, K Gala, S Fanning, ... Nature genetics 45 (12), 1439-1445, 2013 | 1239 | 2013 |
| Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway Z Li, P Razavi, Q Li, W Toy, B Liu, C Ping, W Hsieh, F Sanchez-Vega, ... Cancer cell 34 (6), 893-905. e8, 2018 | 379 | 2018 |
| Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence C Yang, Z Li, T Bhatt, M Dickler, D Giri, M Scaltriti, J Baselga, N Rosen, ... Oncogene 36 (16), 2255-2264, 2017 | 360 | 2017 |
| Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists W Toy, H Weir, P Razavi, M Lawson, AU Goeppert, AM Mazzola, A Smith, ... Cancer discovery 7 (3), 277-287, 2017 | 353 | 2017 |
| PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ... Science translational medicine 7 (283), 283ra51-283ra51, 2015 | 352 | 2015 |
| INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors Q Li, B Jiang, J Guo, H Shao, IS Del Priore, Q Chang, R Kudo, Z Li, ... Cancer discovery 12 (2), 356-371, 2022 | 89 | 2022 |
| Angiomotin-like2 gene (amotl2) is required for migration and proliferation of endothelial cells during angiogenesis Y Wang, Z Li, P Xu, L Huang, J Tong, H Huang, A Meng Journal of Biological Chemistry 286 (47), 41095-41104, 2011 | 83 | 2011 |
| The Amotl2 gene inhibits Wnt/β-catenin signaling and regulates embryonic development in zebrafish Z Li, Y Wang, M Zhang, P Xu, H Huang, D Wu, A Meng Journal of Biological Chemistry 287 (16), 13005-13015, 2012 | 55 | 2012 |
| Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer R Patel, Z Li, BS Zimmerman, MY Fink, JD Wells, X Zhou, K Ayers, ... Breast Cancer Research and Treatment, 1-7, 2022 | 4 | 2022 |
| A systematic analysis of off-label drug use in real-world data (RWD) across more than 145,000 cancer patients. J McCafferty, K Grover, L Li, Z Li, MY Fink, H Goldsweig, M Ma, X Zhou, ... Journal of Clinical Oncology 37 (15_suppl), e18031-e18031, 2019 | 4 | 2019 |
| Abstract P1-17-02: Adaptive and acquired mechanisms of resistance to PI3K inhibitors S Chandarlapaty, M Scaltriti, M Will, Z Li, A Bosch-Campos, S Schwartz, ... Cancer Research 75 (9_Supplement), P1-17-02-P1-17-02, 2015 | 1 | 2015 |
| Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer. MW Kier, Z Li, N Casasanta, R Patel, P Agarwal, BS Zimmerman, Y Yang, ... Journal of Clinical Oncology 40 (16_suppl), 523-523, 2022 | | 2022 |
| Impact of supportive therapies on tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer MW Kier, Z Li, BS Zimmerman, R Patel, Y Yang, MY Fink, JD Wells, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Value-added clinical tumor/normal whole exome and whole transcriptome sequencing versus a DNA and RNA tumor only gene panel for managing breast cancer KS Cole, Z Li, A Tiersten, W Zhang, H Al-Kateb, FM Hantash, MR Rossi, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Abstract P3-09-15: Value-added clinical tumor/normal whole exome and whole transcriptome sequencing versus a DNA and RNA tumor only gene panel for managing breast cancer KS Cole, Z Li, A Tiersten, W Zhang, H Al-Kateb, FM Hantash, MR Rossi, ... Cancer Research 82 (4_Supplement), P3-09-15-P3-09-15, 2022 | | 2022 |
| Phenotyping clinical trial treatment regimens in cancer: An integrative ontology, artificial intelligence and knowledge engineering approach. Y Mai, K Lee, Z Liu, Z Li, S Jones, M Ma, M Fink, K Ghosh, R Chen, ... Journal of Clinical Oncology 38 (15_suppl), e14054-e14054, 2020 | | 2020 |
